Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 24, Pages -Publisher
MDPI
DOI: 10.3390/ijms232416171
Keywords
PARP inhibitor; vasculogenic mimicry; PTX3; NF-kappa B signaling
Funding
- Sorbonne University
Ask authors/readers for more resources
PARPi, as potent inhibitors, can inhibit the formation of vasculogenic mimicry in triple negative breast cancer cells independently of BRCA status. Mechanistically, PARPi trigger and inhibit the NF-kappa B signaling and downregulate the expression of angiogenic factor PTX3.
Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapies that inhibit PARP proteins which are involved in a variety of cell functions. PARPi may act as modulators of angiogenesis; however, the relationship between PARPi and the vasculogenic mimicry (VM) in breast cancer remains unclear. To determine whether PARPi regulate the vascular channel formation, we assessed whether the treatment with olaparib, talazoparib and veliparib inhibits the vascular channel formation by breast cancer cell lines. Here, we found that PARPi act as potent inhibitors of the VM formation in triple negative breast cancer cells, independently of the BRCA status. Mechanistically, we find that PARPi trigger and inhibit the NF-kappa B signaling, leading to the inhibition of the VM. We further show that PARPi decrease the expression of the angiogenic factor PTX3. Moreover, PTX3 rescued the PARPi-inhibited VM inhibition. In conclusion, our results indicate that PARPi, by targeting the VM, may provide a new therapeutic approach for triple negative breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available